| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 36.22 | 77.5% |
| Total Income | 36.22 | 77.5% |
| Expenditure | 25.18 | 10.4% |
| PBT | 44.80 | 2433.3% |
| Net Profit | 37.89 | 1322.3% |
| OPM | 100.00% | 126.28pp |
| NPM | 100.00% | 115.19pp |
| EPS | 0.62 | 1133.3% |
Zevra Reports Q1 2026 Revenue $36.2 Million, Up 78% YoY
07 May 2026 · 7 May, 1:43 am
Summary
Zevra Therapeutics reported a strong first quarter in 2026, with net revenue reaching $36.2 million, a 78% increase compared to the same period last year. The company's performance was driven by continued growth in MIPLYFFA revenue, which amounted to $24.6 million. Zevra also completed the sale of its SDX portfolio for $50.0 million and prepaid its $63.1 million term loan, strengthening its financial position. Net income for the quarter was $37.9 million, a significant improvement from the net loss in Q1 2025.
Key Highlights
- 1
Zevra's Q1 2026 net revenue reached $36.2 million, marking a 78% increase compared to Q1 2025.
- 2
MIPLYFFA net revenue contributed $24.6 million to the total net revenue in Q1 2026.
- 3
The company completed the $50.0 million sale of the SDX portfolio to Commave Therapeutics.
- 4
Zevra prepaid the principal balance on its $63.1 million term loan, resulting in a debt-free balance sheet.
- 5
Net income for Q1 2026 was $37.9 million, or $0.62 per basic share and $0.60 diluted share, compared to a net loss of $(3.1) million in Q1 2025.
- 6
Cash, cash equivalents, and securities totaled $236.8 million as of March 31, 2026.
- 7
Nine MIPLYFFA prescription enrollment forms were received in the U.S. during Q1 2026, bringing the total to 170 since product launch.
Management Comments
Neil F. McFarlane
“We made meaningful progress across the business in the first quarter, led by continued performance for MIPLYFFA, underscoring its role in addressing the needs of patients with Niemann-Pick disease type C,” said Neil F. McFarlane, Zevra's President and Chief Executive Officer. “We also completed the $50.0 million divestiture of the SDX portfolio, and we repaid our term loan debt, sharpening our strategic focus and strengthening our financial position as we execute on our 2026 priorities.”
Informational and educational content only. Not investment advice.